Vimecon CAI Trial for the Interventional Treatment of Paroxysmal Atrial Fibrillation (AF)

Atrial Fibrillation Clinical Trial

— CAI  

Official title:

A Clinical Trial for the Assessment of the Safety and Performance of the Vimecon Laser Cardiac Ablation Instrument (CAI) for the Interventional Treatment of Paroxysmal Atrial Fibrillation (AF)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02770989
• Other study ID #: VMC-001
• Status: Terminated
• Phase: N/A
• Start date: March 2016
• Est. completion date: September 2018

Study information

• Verified date: October 2018
• Source: Vimecon GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a prospective, non-randomized, single arm, multicenter, CE marking trial for patients with paroxysmal atrial fibrillation to undergo an ablation of the cardiac tissue near the PV.

Description:

The objective of this clinical investigation is to confirm the safety and performance of the Vimecon® Laser Cardiac Ablation Instrument when creating scar tissue within the cardiac wall for the treatment of atrial fibrillation.

Up to 66 patients with paroxysmal atrial fibrillation refractory to at least one antiarrhythmic medications (Class I or III) are enrolled. with an expected 10% dropout; 59 per protocol patients are required.

The study duration will be 18 month with a 6 month enrollment period and 12 month follow-up. Interim follow-up visits are at post procedure, 1 Month, 3 Months, 6 Months and 12 Months.

The baseline and follow up tests are standard of care. Additional optional tests are an esophageal endoscopy for determination of potential fistula formation and a cerebral MRI for micro embolism post treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: September 2018
• Est. primary completion date: September 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Aged 18 to 75 years.

2. Patients with intention to be treated for paroxysmal atrial fibrillation. AND unresponsive to =1 antiarrhythmic drug (class I or III) AND at least 2 episodes in the last 12 months, 1 of them documented.

3. Patient should be on an anticoagulation therapy according to the international guidelines (per ACC/AHA//ESC Practice Guidelines)

4. Left atrial (LA) size < 50 mm

5. Symptomatic AF (EHRA-Score = 2)

6. Accessibility of femoral vein and pulmonary veins

7. All patients willing to comply with the study protocol for at least 12 months

Exclusion Criteria:

1. 1. Inability to give written informed consent

2. NYHA Class III and IV

3. Hyperthyroidism

4. Reversible causes of the AF like Pericarditis, Electrolytic imbalance

5. Left Atrial Thrombus formation

6. Structural heart disease disturbing accessibility for AF ablation.

7. Valvular AF, permanent and long-standing persistent AF, currently present Atrial Flutter

8. Any valvular dysfunction more than II°

9. Systemic infections or endocarditis.

10. Impaired left ventricular function with an ejection fraction of less than 35%

11. Kidney dysfunction >Class III with a GFR of less than 35 mL per minute

12. TIA or stroke within the last 6 months

13. Pregnant and breastfeeding Women

14. Previous relevant cardiac surgery (e.g. ASD, PFO, Maze, AICD, pacemaker, congenital heart disorders or valve replacement).

15. Previous ablation of the pulmonary vein.

16. Known or suspected atrial myoma

17. Subject has co-morbid conditions that place the subject at an unacceptable risk (e.g., severe chronic obstructive pulmonary disease, hepatic failure, cerebral degenerative diseases, immunosuppressive abnormalities, hypercoagulable state, nervous system disease and hematological abnormalities.)

18. Contraindicated for the protocol defined anticoagulation plan (per ACC/AHA//ESC Practice Guidelines)

19. Patients with known allergic reactions to the local anesthetic, sedatives, x-ray dye, heparin, protamine, components of the catheter (platinum, iridium, stainless steel) or other agents administered during the procedure.

20. AV-Block IIº and IIIº

21. Contraindication for femoral vein and pulmonary veins access (e.g.: femoral Stent graft, excessive calcification, previous surgical interventions in or adjacent to the femoral veins that impede femoral access)

22. Contraindications for the transseptal approach (e.g.: previous inter-atrial septal patch or surgical interventions in or adjacent to the intro atrial septum)

23. MI in the last 3 months.

24. Enrolled in another clinical trial with a non-CE marked device which has not yet reached its primary endpoint

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Procedure:
• Vimecon Laser CAI percutaneous cardiac ablation
The Vimecon Laser CAI catheter is entered through the femoral vein to access the pulmonary vein (PV) area in the heart in order to ablate the cardiac wall near the PV to create scar tissue and to isolate the PV in order to treat atrial fibrillation.

Locations

Country	Name	City	State
Belgium	ZNA Middelheim	Antwerp
Czechia	Na Homolce Hospital	Prague
Germany	"Herz- und Diabeteszentrum NRW Klinik für Kardiologie"	Bad Oeynhausen

Sponsors (1)

Lead Sponsor	Collaborator
Vimecon GmbH

Countries where clinical trial is conducted

Belgium,  Czechia,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety assessment, free of any Major Adverse Events's or safety events within the first three (3) months after the treatment..	Safety: • Evaluating the proportion of subjects free from experiencing Serious Adverse Events related to the catheter ablation procedure (Major Adverse Events's or safety events) within the first three (3) months after the treatment.; Major adverse events (MAE, Safety events) associated with the catheter ablation procedure include: Cardiac tamponade; Thromboembolic events including pulmonary embolism and stroke; Complete heart block; Acute myocardial infarction; Phrenic nerve palsy; Atrio-esophageal fistula; Vascular complications; Death	< month-3